Latest Breaking News On - Genitourinary cancers symposium - Page 7 : vimarsana.com

Talazoparib + Enzalutamide Beneficial in Metastatic Prostate Cancer

Improvement seen in median imaging-based progression-free survival, regardless of homologous recombination repair status.

'Cancer' Label for Low-Risk Prostate Lesions? Patients Split

But pathologists largely think the name should stay, results of a recent survey show.

Talazoparib + Enzalutamide Beneficial in Metastatic Prostate Cancer

FRIDAY, Feb. 17, 2023 (HealthDay News) For patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 16 to 18 in San Francisco. Neeraj

Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer

Plant-Based Diet Linked to Reduced Risk for Prostate Cancer Progression

THURSDAY, Feb. 16, 2023 (HealthDay News) Plant-based diets are associated with a reduced risk for prostate cancer (PC) progression and recurrence, according to a study presented at the American